Aeterna Zentaris Inc
TSX:AEZS

Watchlist Manager
Aeterna Zentaris Inc Logo
Aeterna Zentaris Inc
TSX:AEZS
Watchlist
Price: 5.1 CAD -0.97%
Market Cap: 18.9m CAD

Aeterna Zentaris Inc
Net Change in Cash

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Aeterna Zentaris Inc
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
Aeterna Zentaris Inc
TSX:AEZS
Net Change in Cash
-$17m
CAGR 3-Years
N/A
CAGR 5-Years
-5%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Change in Cash
-$1.6B
CAGR 3-Years
-67%
CAGR 5-Years
10%
CAGR 10-Years
N/A
Gilead Sciences Inc
NASDAQ:GILD
Net Change in Cash
$2.3B
CAGR 3-Years
90%
CAGR 5-Years
-8%
CAGR 10-Years
-11%
Amgen Inc
NASDAQ:AMGN
Net Change in Cash
$434m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Change in Cash
-$300.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Change in Cash
$501.3m
CAGR 3-Years
103%
CAGR 5-Years
22%
CAGR 10-Years
51%
No Stocks Found

Aeterna Zentaris Inc
Glance View

Market Cap
18.9m CAD
Industry
Biotechnology

Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The company is headquartered in Montreal, Quebec and currently employs 17 full-time employees. The firm's lead product, Macrilen (macimorelin), is an oral test indicated for the diagnosis of patients with adult growth hormone deficiency (AGHD). Macrilen (macimorelin) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor (GHSR-1a) and has uses in both endocrinology and oncology indications. The firm is also leveraging the clinical and compelling safety profile of macimorelin to develop it for the diagnosis of childhood-onset growth hormone deficiency (CGHD). The company is also developing oral prophylactic bacterial vaccines against each of SARS-CoV-2, the virus that causes COVID-19, and Chlamydia Trachomatis. The firm focuses on the commercialization of macimorelin in Asia and the rest of the world.

AEZS Intrinsic Value
Not Available

See Also

What is Aeterna Zentaris Inc's Net Change in Cash?
Net Change in Cash
-17m USD

Based on the financial report for Mar 31, 2024, Aeterna Zentaris Inc's Net Change in Cash amounts to -17m USD.

What is Aeterna Zentaris Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 5Y
-5%

Over the last year, the Net Change in Cash growth was 0%.

Back to Top